Indeed we found increased expression levels for RMS-markers (Myog, Myl4, Igf2, Prox1), a FS-gene (Vcan), and LS-related genes (Pparg, Myo1e, Hoxa5, Plau), which further established the MD-tumors as mixed sarcomas consisting of RMS, FS and LS-compartments (Figure S1). The gene discussed is IGF2; the disease is sarcoma.